ConductScience.org, home

Paper39796175

The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

Pedrani M and 12 others. Int J Mol Sci, 2025. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages. Papers, record 39796175. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796175

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
2.48, provisional
iCite
Revised in PubMed
2025-01-13
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pedrani MMartinohttps://orcid.org/0000-0002-8502-8226
2Barizzi JJessica
3Salfi GGiuseppehttps://orcid.org/0000-0003-4953-0339
4Nepote AAlessandro
5Testi IIrene
6Merler SSarahttps://orcid.org/0000-0002-8691-6284
7Castelo-Branco LLuis
8Mestre RPRicardo Pereirahttps://orcid.org/0000-0002-3123-3697
9Turco FFabio
10Tortola LLuigi
11Theurillat JPJean-Philippe
12Gillessen SSilkehttps://orcid.org/0000-0001-5746-6555
13Vogl UUrsulahttps://orcid.org/0000-0002-2046-4246

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Prostatic NeoplasmsMajor topic
Biomarkers, TumorMajor topic
PTEN PhosphohydrolaseMajor topic
Humans
Male
Prognosis
Genes, Tumor Suppressor
Neoplasm Staging
Tumor Suppressor Protein p53

Source PubMed

Download CSV of topics

References207

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023https://conductscience.org/library/papers/37003085PubMed
226000489Integrative clinical genomics of advanced prostate cancer.Cell2015https://conductscience.org/library/papers/26000489PubMed
322000013Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.Cell2011https://conductscience.org/library/papers/22000013PubMed
435176163A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2022https://conductscience.org/library/papers/35176163PubMed
539577422Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.Cancer Cell2024https://conductscience.org/library/papers/39577422PubMed
628411207Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Cancer Discov2017https://conductscience.org/library/papers/28411207PubMed
738729054Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.Eur J Cancer2024https://conductscience.org/library/papers/38729054PubMed
823222491Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.Mod Pathol2013https://conductscience.org/library/papers/23222491PubMed
935179959RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.Sci Adv2022https://conductscience.org/library/papers/35179959PubMed
1023649003Platinum-based chemotherapy for variant castrate-resistant prostate cancer.Clin Cancer Res2013https://conductscience.org/library/papers/23649003PubMed
1130037818Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.Clin Cancer Res2019https://conductscience.org/library/papers/30037818PubMed
1215472903Expression patterns of potential therapeutic targets in prostate cancer.Int J Cancer2005https://conductscience.org/library/papers/15472903PubMed
1325691773Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.Clin Cancer Res2015https://conductscience.org/library/papers/25691773PubMed
1438136389Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.Cancers (Basel)2023https://conductscience.org/library/papers/38136389PubMed
1530553611Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.Eur Urol2019https://conductscience.org/library/papers/30553611PubMed
1630033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018https://conductscience.org/library/papers/30033370PubMed
1725056375Evidence for molecular differences in prostate cancer between African American and Caucasian men.Clin Cancer Res2014https://conductscience.org/library/papers/25056375PubMed
1828068672Genomic hallmarks of localized, non-indolent prostate cancer.Nature2017https://conductscience.org/library/papers/28068672PubMed
1923545904Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.Prostate Cancer Prostatic Dis2013https://conductscience.org/library/papers/23545904PubMed
2035688662Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.Eur Urol2022https://conductscience.org/library/papers/35688662PubMed

See all 207 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42794743Young Aggressive Prostate Tumors Exhibit Increased Genomic Instability and an Exploratory RNA-CNA-Concordant Transcriptomic Pattern.Int J Mol Sci2026https://conductscience.org/library/papers/42794743PubMed
42427857Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.Res Sq2026https://conductscience.org/library/papers/42427857PubMed
42279286Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42279286PubMed
42246034Toward the genetic landscape of prostate cancer in India: insights from whole-exome and low-pass whole-genome sequencing of formalin-fixed paraffin-embedded tumor tissues.Front Syst Biol2026https://conductscience.org/library/papers/42246034PubMed
42028056Penile metastasis from prostate adenocarcinoma: A case report and review of the literature.SAGE Open Med Case Rep2026https://conductscience.org/library/papers/42028056PubMed
41878526Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study.Front Oncol2026https://conductscience.org/library/papers/41878526PubMed
41543663The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving 177Lutetium-PSMA-therapy.Insights Imaging2026https://conductscience.org/library/papers/41543663PubMed
41375007Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.Cancers (Basel)2025https://conductscience.org/library/papers/41375007PubMed
40508118
Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.
Int J Mol Sci2025https://conductscience.org/library/papers/40508118PubMed
40427204Echolaser Focal Treatment for Prostate Cancer Guided by Fiducial Marker Placement.Cancers (Basel)2025https://conductscience.org/library/papers/40427204PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene
RB15925PubTator's text mininghttps://conductscience.org/library/genes/5925NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene
TWSG157045PubTator's text mininghttps://conductscience.org/library/genes/57045NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39796175

GET https://conductscience.org/api/papers/v1/39796175/references?page=2